Hydreight Technologies Expands GLP-1 Telehealth Suite with Launch of Liraglutide on VSDHOne Platform
Hydreight Technologies (HYDTF) has expanded its VSDHOne platform by launching Liraglutide, enhancing its GLP-1 weight management portfolio. The company's comprehensive GLP-1 offerings now include Semaglutide (weekly injectable), Tirzepatide (dual-action, weekly injectable), Liraglutide (daily injectable), and Sublingual & Buccal GLP-1s (needle-free administration).
The addition of Liraglutide introduces a stable, patent-free option amid increasing GLP-1 medication demand. The VSDHOne platform facilitates telehealth consultation, prescription, and nationwide delivery across 50 US states. With over 400 licenses sold across the U.S., Hydreight's platform supports multiple delivery methods including injectables, sublingual, and buccal options.
Notable achievements include ranking 56th on the 2024 Deloitte Technology Fast 500™, recognition as a Top 50 TSX Venture Exchange Company, and ranking 13th among Americas' Fastest Growing Companies by Financial Times in 2025.
Hydreight Technologies (HYDTF) ha ampliato la sua piattaforma VSDHOne lanciando Liraglutide, arricchendo il suo portafoglio di prodotti GLP-1 per la gestione del peso. L'offerta completa di GLP-1 dell'azienda include ora Semaglutide (iniettabile settimanale), Tirzepatide (azione doppia, iniettabile settimanale), Liraglutide (iniettabile giornaliero) e GLP-1 sublinguali e buccali (somministrazione senza ago).
L'introduzione di Liraglutide offre un'opzione stabile e priva di brevetto in un mercato con domanda crescente di farmaci GLP-1. La piattaforma VSDHOne consente consulenze telemediche, prescrizioni e consegne a livello nazionale in tutti i 50 stati degli USA. Con oltre 400 licenze vendute negli Stati Uniti, la piattaforma di Hydreight supporta diversi metodi di somministrazione, inclusi iniettabili, sublinguali e buccali.
Tra i risultati più significativi si annoverano il 56° posto nella classifica Deloitte Technology Fast 500™ del 2024, il riconoscimento come una delle Top 50 aziende della TSX Venture Exchange e il 13° posto tra le aziende a più rapida crescita delle Americhe secondo il Financial Times nel 2025.
Hydreight Technologies (HYDTF) ha ampliado su plataforma VSDHOne lanzando Liraglutide, mejorando su portafolio de GLP-1 para el manejo del peso. La oferta integral de GLP-1 de la compañía ahora incluye Semaglutide (inyectable semanal), Tirzepatide (acción dual, inyectable semanal), Liraglutide (inyectable diario) y GLP-1 sublinguales y bucales (administración sin aguja).
La incorporación de Liraglutide ofrece una opción estable y libre de patentes en medio de una creciente demanda de medicamentos GLP-1. La plataforma VSDHOne facilita consultas de telesalud, prescripciones y entregas a nivel nacional en los 50 estados de EE.UU. Con más de 400 licencias vendidas en todo el país, la plataforma de Hydreight soporta múltiples métodos de administración, incluyendo inyectables, sublinguales y bucales.
Los logros destacados incluyen el puesto 56 en el Deloitte Technology Fast 500™ de 2024, el reconocimiento como una de las 50 principales empresas de la TSX Venture Exchange y el puesto 13 entre las empresas de más rápido crecimiento en América según Financial Times en 2025.
Hydreight Technologies (HYDTF)는 VSDHOne 플랫폼을 확장하여 리라글루타이드를 출시하며 GLP-1 체중 관리 포트폴리오를 강화했습니다. 회사의 종합적인 GLP-1 제품군에는 세마글루타이드(주 1회 주사), 티르제파타이드 (이중 작용, 주 1회 주사), 리라글루타이드 (일일 주사), 그리고 바늘 없이 투여 가능한 설하 및 협점막 GLP-1이 포함됩니다.
리라글루타이드 추가는 증가하는 GLP-1 약물 수요 속에서 안정적이고 특허가 없는 옵션을 제공합니다. VSDHOne 플랫폼은 원격 진료 상담, 처방, 미국 50개 주 전역에 걸친 배송을 지원합니다. 미국 전역에서 400개 이상의 라이선스가 판매되었으며, Hydreight의 플랫폼은 주사제, 설하제, 협점막제 등 다양한 투여 방식을 지원합니다.
주요 성과로는 2024년 Deloitte Technology Fast 500™에서 56위, TSX 벤처 거래소 상위 50개 기업 선정, 2025년 Financial Times가 선정한 아메리카에서 가장 빠르게 성장하는 기업 13위 등이 있습니다.
Hydreight Technologies (HYDTF) a étendu sa plateforme VSDHOne en lançant le Liraglutide, renforçant ainsi son portefeuille GLP-1 pour la gestion du poids. L'offre complète en GLP-1 de l'entreprise comprend désormais Sémaglutide (injection hebdomadaire), Tirzépatide (action double, injection hebdomadaire), Liraglutide (injection quotidienne) ainsi que des GLP-1 sublinguaux et buccaux (administration sans aiguille).
L'ajout du Liraglutide propose une option stable et sans brevet dans un contexte de demande croissante pour les médicaments GLP-1. La plateforme VSDHOne facilite les consultations en télésanté, les prescriptions et la livraison à l'échelle nationale dans les 50 États américains. Avec plus de 400 licences vendues à travers les États-Unis, la plateforme de Hydreight supporte plusieurs modes d'administration, incluant les injections, les formes sublinguales et buccales.
Parmi les réalisations notables figurent la 56e place au Deloitte Technology Fast 500™ 2024, la reconnaissance comme l'une des 50 meilleures entreprises de la TSX Venture Exchange, ainsi que la 13e place parmi les entreprises à la croissance la plus rapide des Amériques selon le Financial Times en 2025.
Hydreight Technologies (HYDTF) hat seine VSDHOne-Plattform erweitert und Liraglutid eingeführt, wodurch das GLP-1-Gewichtsmanagement-Portfolio verbessert wurde. Das umfassende GLP-1-Angebot des Unternehmens umfasst nun Semaglutid (wöchentliche Injektion), Tirzepatid (dual wirkend, wöchentliche Injektion), Liraglutid (tägliche Injektion) sowie sublinguale und bukkale GLP-1-Präparate (nadelfreie Verabreichung).
Die Aufnahme von Liraglutid bietet eine stabile, patentfreie Option angesichts der steigenden Nachfrage nach GLP-1-Medikamenten. Die VSDHOne-Plattform ermöglicht Telemedizin-Konsultationen, Verschreibungen und landesweite Lieferung in allen 50 US-Bundesstaaten. Mit über 400 verkauften Lizenzen in den USA unterstützt Hydreight mehrere Verabreichungsmethoden, darunter Injektionen sowie sublinguale und bukkale Optionen.
Zu den bemerkenswerten Erfolgen zählen der 56. Platz im Deloitte Technology Fast 500™ 2024, die Anerkennung als Top 50 Unternehmen an der TSX Venture Exchange und der 13. Platz unter den am schnellsten wachsenden Unternehmen Amerikas laut Financial Times 2025.
- Expansion of product portfolio with patent-free Liraglutide addition
- Nationwide presence with over 400 licenses across 50 US states
- Multiple delivery methods offering competitive advantage
- Recognition as one of Americas' fastest-growing companies
- Established infrastructure for telehealth consultations and nationwide delivery
- Daily injection requirement for Liraglutide vs. weekly options
- Lower bioavailability in sublingual/buccal delivery methods compared to injectables
Liraglutide Offers Long-Term Stability and Expands Hydreight’s Comprehensive GLP-1 Weight Management Portfolio
VANCOUVER, British Columbia and LAS VEGAS, April 15, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight”or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is pleased to announce the expansion of its VSDHOne platform with the launch of Liraglutide. This addition marks a strategic expansion of Hydreight’s growing GLP-1 weight management and wellness offerings, strengthening its commitment to accessible and innovative solutions through its national telehealth network.
Hydreight’s current GLP-1 offerings now include:
- Semaglutide (weekly injectable)
- Tirzepatide (dual-action, weekly injectable)
- Liraglutide (newly launched, daily injectable)
- Sublingual & Buccal GLP-1s (needle-free administration)
These offerings include a range of delivery methods to meet the diverse needs of patients and providers—from weekly or daily injectables to sublingual and buccal formats. Sublingual doses are dissolved under the tongue, and buccal is absorbed through the cheek, offering flexibility for those who prefer not to use needles while maintaining consistent dosage options. This variety ensures tailored, scalable solutions for weight management and metabolic care.
A Strategic Addition for Stability & Choice
As demand for GLP-1 medications surges, Hydreight’s inclusion of Liraglutide introduces a stable, patent-free, and clinically proven option—ideal for patients and providers seeking consistent long-term therapies amid evolving supply and regulatory landscapes. Unlike newer GLP-1 entrants, Liraglutide’s established track record and daily dosing format offer flexibility without compromising efficacy.
“The launch of Liraglutide further deepens our commitment to expanding access to proven GLP-1 therapies,” said Shane Madden, CEO of Hydreight. “It doesn’t replace anything—it expands our offering. No matter how the landscape shifts, Hydreight users can count on a complete and reliable GLP-1 portfolio.”
Why Liraglutide?
Liraglutide is a GLP-1 receptor agonist used in the management of obesity and type 2 diabetes. Delivered via once-daily injection, it offers consistent and clinically proven efficacy. Compared to sublingual GLP-1s, which have lower bioavailability and shorter duration of action, Liraglutide’s injectable form ensures direct systemic absorption and predictable, long-lasting effects.
Comprehensive & Customizable Delivery Options Hydreight’s GLP-1 portfolio now supports multiple delivery methods:
- Injectables: Weekly, biweekly, or daily based on patient needs
- Sublingual: Dissolved under the tongue
- Buccal: Absorbed through the inner cheek
This mix of injectable, sublingual, and buccal options positions Hydreight as a category leader in GLP-1 administration versatility. It allows medical professionals to provide customized, scalable care while ensuring patient adherence and comfort.
Unlocking Access via VSDHOne
The VSDHOne platform enables a seamless patient journey—from telehealth consultation to prescription and nationwide delivery. It supports medical professionals with flexible tools while ensuring regulatory compliance across all services.
“Hydreight isn’t just a tech stack—we’re a full-service medical infrastructure,” added Madden. “With over 400 licenses sold across the U.S., we’re creating a scalable, future-ready solution for wellness, weight loss, and personalized healthcare.”
The addition of Liraglutide and sublingual/buccal routes of administration for the GLP1s reflects Hydreight’s mission to expand access to premium wellness and weight management therapies through a convenient, compliant, and nationwide telehealth network. The VSDHOne platform simplifies the entire patient journey from telehealth consult to prescription and delivery, while offering medical professionals the flexibility to provide treatments at scale.
Liraglutide will be available to all eligible VSDHOne customers, ensuring widespread access to these innovative wellness treatments.
On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company
Hydreight Technologies Recognized by the Financial Times Ranking 13th as One of the Americas’ Fastest Growing Companies in 2025
Contact
Email: ir@hydreight.com; Telephone: 1 (702) 970-8112
About Hydreight Technologies Inc.
Hydreight Technologies Inc is building one of the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.
This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
About VSDHOne - Direct to Consumer Platform
Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s (semaglutide, tirzepatide, liraglutide), peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, path to profitability, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “projecting”, “expect” or similar expressions and includes information regarding expectations for the Company's growth,
Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
FAQ
What new product has Hydreight (HYDTF) added to its GLP-1 portfolio in April 2025?
How many delivery methods does Hydreight (HYDTF) offer for GLP-1 medications?
What is the geographical reach of Hydreight's (HYDTF) mobile clinical network?
What recent rankings has Hydreight (HYDTF) achieved in 2024-2025?
